Cu-CPT22

Catalog No.S8677 Batch:S867701

Print

Technical Data

Formula

C19H22O7
Molecular Weight 362.37 CAS No. 1416324-85-0
Solubility (25°C)* In vitro DMSO 72 mg/mL (198.69 mM)
Ethanol 9 mg/mL (24.83 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
10%DMSO 40%PEG300 5%Tween80 45%ddH2O
3.6mg/ml Taking the 1 mL working solution as an example, add 100 μL of 36 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify it; then continue to add 450 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description CU-CPT22 shows dose-dependent inhibitory effects blocking Pam3CSK4-induced TLR1/2 activation with an IC50 of 0.58 ± 0.09 µM while no significant inhibition to TLR2/6. It demonstrates minimal non-specific inhibition against a panel of 10 representative kinases (PDGFRB, MET, DDR2, SRC, MAPK1, PAK1, AKT1, PKC-γ, CAMK1, and PLK4).
Targets
TLR1/2 [1]
(Cell-free)
0.58 μM
In vitro

CU-CPT22 can compete with the synthetic triacylated lipoprotein (Pam3CSK4) binding to TLR1/2 with high inhibitory activity and specificity. The inhibition constant (Ki) is 0.41 ± 0.07 µM. CU-CPT22 inhibits TLR1/2 signaling without affecting other TLRs, showing it is highly selective in intact cells. It has no significant cytotoxicity at various concentrations up to 100 µM in RAW 264.7 cells using MTT assay. Kinase profiling shows that CU-CPT22 demonstrates minimal non-specific inhibition against a panel of 10 representative kinases (PDGFRB, MET, DDR2, SRC, MAPK1, PAK1, AKT1, PKC-γ, CAMK1, and PLK4). CU-CPT22 suppresses TLR1/2-mediated inflammation response. It inhibits about 60% of TNF-α and 95% of IL-1β at 8 µM in the RAW 264.7 cells[1].
In vivo

Cu-CPT22 administered before myocardial infarction (MI) significantly suppresses MI-induced upregulation of kidney injury molecule-1 (KIM-1), TLR2, TLR4, MyD88, and chemokine (C-C motif) ligand 2 levels and activation of NF-κB, whereas neutrophil gelatinase-associated lipocalin (NGAL) levels and IL-6 and TNF-α expression levels are unchanged[2].

Protocol (from reference)

Cell Assay:

[3]
  • Cell lines

    MUTZ-3-derived Langerhans cells (MUTZ-LCs)

  • Concentrations

    10 and 25 μM

  • Incubation Time

    1 h

  • Method

    MUTZ-LCs are seeded in alpha medium without supple-ments and exposed to different microbial and pro-inflammatorystimuli for 24 h (2.5 × 105 cells/ml): 1 μg/ml Pam3CSK4, 1 μg/mlPam2CSK4, 1 μg/ml poly(A:U), 1 μg/ml poly(I:C), 1 μg/ml ultrapurelipopolysaccharide (LPS) from Escherichia coli serotype 0111:B4, 50 ng/ml rh-TNF-α, 30 ng/ml rh-IL-1β, or a cytokine maturation cocktail(CMC) consisting of 50 ng/ml rh-TNF-α, 25 ng/ml rh-IL-1β,100 ng/ml rh-IL-6 and 1 μg/ml PGE2. Cytokines produced in E. coli, contained low endotoxinlevels (≤1.0 EU/μg cytokine) as determined by Limulus Amebo-cyte Lysate (LAL) assay. As control MUTZ-LCs (2.5 × 105 cells/ml) are maintained for 24 hor 48 h in alpha medium only. The TLR2/1 antagonist CU-CPT22 is applied 1 h before stimulation with Pam3CSK4 and Pam2CSK4, respectively.
Animal Study:

[2]
  • Animal Models

    Male LETO and OLETF rats

  • Dosages

    3 mg/kg

  • Administration

    i.p.

Selleck's Cu-CPT22 has been cited by 7 publications

Bifidobacterium adolescentis induces Decorin+ macrophages via TLR2 to suppress colorectal carcinogenesis [ J Exp Clin Cancer Res, 2023, 42(1):172] PubMed: 37464382
Tongue sole creatine kinases function as DAMP and activate antimicrobial immunity via TLR2 [ Front Immunol, 2023, 14:1142488] PubMed: 36936949
Lactobacillus johnsonii alleviates colitis by TLR1/2-STAT3 mediated CD206+ macrophagesIL-10 activation [ Gut Microbes, 2022, 14(1):2145843] PubMed: 36398889
SAA1/TLR2 axis directs chemotactic migration of hepatic stellate cells responding to injury [ iScience, 2021, 24(5):102483] PubMed: 34113824
MPMBP down-regulates Toll-like receptor (TLR) 2 ligand-induced proinflammatory cytokine production by inhibiting NF-κB but not AP-1 activation. [ Int Immunopharmacol, 2020, 79:106085] PubMed: 31901621
Autophagy Inhibition and Inammation Activation Induced by Phosphorylated Alpha-synuclein Through Toll-like Receptor 2 Pathway in the Hippocampus of MPTP Mouse Model of Parkinson’s Disease Contribute to Its Cognitive Function Decline in the Early Stage [ Research Square, 2020, 10.21203/rs.3.rs-126752/v1] PubMed: N/A
Autophagy Inhibition and Inflammation Activation Induced by Phosphorylated Alpha-synuclein Through Toll-like Receptor 2 Pathway in the Hippocampus of [ Research Square, 2020, 10.21203/rs.3.rs-126752/v1] PubMed: None

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.